A Placebo- and Active-Controlled Assessment of 6- and 50-mg Oral Doxepin on Cardiac Repolarization in Healthy Volunteers: A Thorough QT Evaluation

Trial Profile

A Placebo- and Active-Controlled Assessment of 6- and 50-mg Oral Doxepin on Cardiac Repolarization in Healthy Volunteers: A Thorough QT Evaluation

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2011

At a glance

  • Drugs Doxepin; Moxifloxacin
  • Indications Bacterial infections; Insomnia
  • Focus Pharmacodynamics
  • Sponsors Ocera Therapeutics; Somaxon Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2011 New trial record
    • 29 Jun 2011 Results published in the Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top